Article

Acral myxoinflammatory fibroblastic sarcoma: case series and immunohistochemical analysis

Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
Journal of Cutaneous Pathology (Impact Factor: 1.56). 02/2008; 35(2):192-6. DOI: 10.1111/j.1600-0560.2007.00791.x
Source: PubMed

ABSTRACT Acral myxoinflammatory fibroblastic sarcoma (AMFS) is a rare, low-grade neoplasm most often occurring on the extremities of adults. It consists of mixed inflammatory infiltrates with nodules of epithelioid, spindled and bizarre-appearing cells within a fibrosclerotic-to-myxoid stroma. AMFS frequently recurs, but only rarely metastasizes.
A retrospective analysis of all cases of AMFS seen in the past 4 years from the Stanford University Laboratory of Surgical Pathology and collaborating institutions was performed. We sought to better characterize the clinicopathologic characteristics of this rare tumor. Immunohistochemical stains, including CD34, epithelial membrane antigen (EMA), epidermal growth factor receptor (EGFR), CD117, CD163, Ki67 and p53, were also performed.
Eighteen cases were analyzed, and clinical information was available on 13 of them. The mean age at diagnosis was 48 years old, 10/13 (77%) occurred on the distal extremities and diameter of the lesions ranged from 1.0 to 10.0 cm. Treatment included wide local or radical excision and local recurrences were not reported. Many of the lesions were multinodular. Histologic characteristics included the presence of fibrosclerotic and myxoid stroma, sheets of spindled to round epithelioid cells, Reed-Sternberg or virocyte-like cells, lipoblast-like cells and rare mitotic figures. In most cases, CD34, EGFR and CD163 were diffusely positive. EMA and CD117 were weakly positive in some cases. Ki67 labeled < 10% of cells, and staining with P53 was variable.
Because AMFS may be mistaken for lymphoma, infection or tumors with higher metastatic potential, correct diagnosis is important to avoid unnecessary procedures and allow for proper clinical management. EGFR positivity suggests possible therapeutic use in aggressive cases.

0 Followers
 · 
242 Views
  • Source
    • "3/18 0/18 11-319 Lambert et al., 2001 [14] 1 53 1/1 Excision 7.4 NA NA NA Jurcic et al., 2002 [15] 9 22-87 6/9 Excision, 6 amputation 1.5-1.8 1/9 0/9 1-60 Sakaki et al., 2003 [16] 5 15-75 5/5 Excision 2.7 2/4 1/4 8-58 Kusumi et al., 2005 [17] 1 58 1/1 Excision 4.9 0/1 0/1 12 Lang et al., 2006 [18] 5 22-66 4/5 Excision NA 0/5 0/5 14-22 Narvaez et al., 2007 [8] 4 22-66 3/4 Excision NA 0/4 0/4 NA Yasuda et al., 2007 [19] 1 68 1/1 Excision NA 0/1 0/1 48 Hassanein et al., 2008 [20] 5 39-65 5/5 3 excision, 1 amputation, 1 loss to follow-up 1.4.0 2/4 1/4 0.5-95 Kovarik et al., 2008 [12] 18 21-66 10/18 Excision 1.0-10.0 0/13 0/13 1-23 Chahdi et al., 2010 [21] 1 51 1/1 Excision 3 0/1 0/1 10 Fukasawa et al., 2012 [22] 1 48 1/1 Excision 2 0/1 0/1 24 Wickham et al., 2012 [23] 1 40 1/1 Excision 3.5 0/1 0/1 NA Ertener et al., 2013 [10] 1 53 1/1 Excision 2 0/1 0/1 7 Silver et al., 2013 [24] 1 33 1/1 Excision 2 1/1 0/1 60 Toll et al., 2013 [25] 3 40-70 3/3 2 excision, 1 amputation NA 1/3 0/3 24-84 Raghavan et al., 2012 [26] 1 50 1/1 Excision 6 0/1 0/1 24 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare low-grade, malignant soft tissue tumor that is usually observed in the extremities of adult patients. Magnetic resonance imaging (MRI) findings for this tumor type have rarely been reported. We report a case involving the distal left femur of a middle-aged man and tumoral invasion of the bone, which, to our knowledge, has been previously described only once. He was treated by distal femoral tumor resection and reconstruction with a modular prosthesis. Histopathologic diagnosis confirmed MIFS. We reviewed literature of the diagnostic imaging and bone invasion findings associated with this tumor type.
    Ai zheng = Aizheng = Chinese journal of cancer 07/2014; 33(8). DOI:10.5732/cjc.014.10049
  • Journal of the American Academy of Dermatology 04/2010; 62(4):711-2. DOI:10.1016/j.jaad.2008.09.026 · 5.00 Impact Factor
  • Journal of the American Academy of Dermatology 04/2010; 62(4):712-5. DOI:10.1016/j.jaad.2008.09.055 · 5.00 Impact Factor
Show more